1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

MedPAC’s Part B Options Include ‘Value-Based’ Payment During Accelerated Approval

 
• By Michael McCaughan

Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.

Unrecognizable diagnostician presenting a value-based health care model. Medical and healthcare concept for finding and improving hospital care quality, reimbursement, private health insurance. - Image
• Source: Shutterstock

The US Medicare Payment Advisory Commission’s initial list of ideas to overhaul payment for drugs in the physician-administered Part B setting includes applying cost-effectiveness benchmarks for new drugs and biologics approved via the Accelerated Approval pathway.

At its 7 October meeting, MedPAC began consideration of proposals to address the “high prices” of drugs covered under Part...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

Oz Hints That Medicare Action On GLP-1s And Weight Loss Coming

 
• By Sarah Karlin-Smith

CMS Administrator Oz punted on a GLP-1 question in an interview, suggesting it was because his agency will be acting soon.

GLOBE Medicare Pricing Model: MFN Bargaining Chip Or Part Of Broad Reform Agenda?

 
• By Cathy Kelly

For manufacturers, the model could lead to a substantial reductions in prices for high cost physician administered drugs in Medicare, Medicaid and the 340B program.

Pink Sheet Podcast: Government Shutdown’s Impact On US FDA, Pfizer Inks Drug Pricing Deal

 
• By Derrick Gingery, Sarah Karlin-Smith, Cathy Kelly, and Sue Sutter

Pink Sheet reporter and editors discuss the issues that could arise for the FDA as it navigates the government shutdown, as well as the aftershocks of Pfizer’s drug pricing deal with the White House.

Medicare Delays Combo Drug Negotiation Policy One Year

 
• By Cathy Kelly

CMS said the policy may be modified next year in rulemaking on the negotiation program.

More from Government Payers

Shutdown Day One: US FDA Hiring, MFN Demos Delayed?

 
• By Derrick Gingery and Cathy Kelly

The FDA’s search for hundreds of new employees, as well as the CMS Most Favored Nation pricing demonstration project, could be delayed by the ongoing government shutdown.

Questions Persist About How Pfizer’s US Agreement Lowers Prices

 
• By Jessica Merrill

By choosing a confidential agreement with the US government over announcing the details of the deal, Pfizer continues industry’s legacy of pricing secrecy.

Closing The Gap? Pfizer Will Set Same US, Foreign Launch Prices In MFN Deal

 
• By Cathy Kelly

The company’s agreement with the Trump Administration, which likely is a template for MFN deals with other companies, also includes a $70bn commitment to ‘reshoring’ development and manufacturing in the US.